AU2015235852B2 - Polypeptides, cells, and methods involving engineered CD16 - Google Patents

Polypeptides, cells, and methods involving engineered CD16 Download PDF

Info

Publication number
AU2015235852B2
AU2015235852B2 AU2015235852A AU2015235852A AU2015235852B2 AU 2015235852 B2 AU2015235852 B2 AU 2015235852B2 AU 2015235852 A AU2015235852 A AU 2015235852A AU 2015235852 A AU2015235852 A AU 2015235852A AU 2015235852 B2 AU2015235852 B2 AU 2015235852B2
Authority
AU
Australia
Prior art keywords
cell
cells
polypeptide
cd16a
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015235852A
Other languages
English (en)
Other versions
AU2015235852A1 (en
Inventor
Yawu JING
Dan Samuel Kaufman
Zhenya NI
Bruce Kenneth Walcheck
Jianming Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of AU2015235852A1 publication Critical patent/AU2015235852A1/en
Application granted granted Critical
Publication of AU2015235852B2 publication Critical patent/AU2015235852B2/en
Priority to AU2019250155A priority Critical patent/AU2019250155B2/en
Priority to AU2022204134A priority patent/AU2022204134B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2015235852A 2014-03-28 2015-03-27 Polypeptides, cells, and methods involving engineered CD16 Active AU2015235852B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019250155A AU2019250155B2 (en) 2014-03-28 2019-10-16 Polypeptides, cells, and methods involving engineered cd16
AU2022204134A AU2022204134B2 (en) 2014-03-28 2022-06-14 Polypeptides, cells, and methods involving engineered cd16

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971996P 2014-03-28 2014-03-28
US61/971,996 2014-03-28
PCT/US2015/022998 WO2015148926A1 (en) 2014-03-28 2015-03-27 Polypeptides, cells, and methods involving engineered cd16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019250155A Division AU2019250155B2 (en) 2014-03-28 2019-10-16 Polypeptides, cells, and methods involving engineered cd16

Publications (2)

Publication Number Publication Date
AU2015235852A1 AU2015235852A1 (en) 2016-10-20
AU2015235852B2 true AU2015235852B2 (en) 2019-08-15

Family

ID=52829414

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015235852A Active AU2015235852B2 (en) 2014-03-28 2015-03-27 Polypeptides, cells, and methods involving engineered CD16
AU2019250155A Active AU2019250155B2 (en) 2014-03-28 2019-10-16 Polypeptides, cells, and methods involving engineered cd16
AU2022204134A Active AU2022204134B2 (en) 2014-03-28 2022-06-14 Polypeptides, cells, and methods involving engineered cd16

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019250155A Active AU2019250155B2 (en) 2014-03-28 2019-10-16 Polypeptides, cells, and methods involving engineered cd16
AU2022204134A Active AU2022204134B2 (en) 2014-03-28 2022-06-14 Polypeptides, cells, and methods involving engineered cd16

Country Status (9)

Country Link
US (4) US10464989B2 (cg-RX-API-DMAC7.html)
EP (2) EP4227318A1 (cg-RX-API-DMAC7.html)
JP (4) JP6795399B2 (cg-RX-API-DMAC7.html)
CN (2) CN113699159A (cg-RX-API-DMAC7.html)
AU (3) AU2015235852B2 (cg-RX-API-DMAC7.html)
CA (1) CA2944199C (cg-RX-API-DMAC7.html)
ES (1) ES2941679T3 (cg-RX-API-DMAC7.html)
PT (1) PT3122769T (cg-RX-API-DMAC7.html)
WO (1) WO2015148926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015235852B2 (en) 2014-03-28 2019-08-15 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
PT3371314T (pt) * 2015-11-04 2023-08-31 Fate Therapeutics Inc Modificação genómica de células pluripotentes
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3007996A1 (en) * 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
AU2017207906B2 (en) 2016-01-15 2021-03-11 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
EP3426777B1 (en) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
US20180273903A1 (en) * 2016-12-30 2018-09-27 Celularity, Inc. Genetically modified natural killer cells
US20200283501A1 (en) * 2017-10-26 2020-09-10 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
KR20250048610A (ko) * 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
JP7575271B2 (ja) 2018-03-29 2024-10-29 フェイト セラピューティクス，インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
MX2021006194A (es) 2018-12-02 2021-06-30 Fate Therapeutics Inc Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
US20230355759A1 (en) * 2019-07-31 2023-11-09 Celularity Inc. Populations of natural killer cells comprising a cleavage resistant cd16
WO2021113849A1 (en) * 2019-12-05 2021-06-10 Celularity Inc. Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
EP4168538A4 (en) * 2020-06-19 2024-03-20 Fate Therapeutics, Inc. COMBINATION OF IPSC-DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4255922A1 (en) 2020-12-03 2023-10-11 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CA3205748A1 (en) * 2021-01-21 2022-07-28 Haishan LI Engineered nk cells and methods of treating cancer
KR102894135B1 (ko) * 2021-09-29 2025-12-04 카오티에스 주식회사 신규한 재조합 Fc 수용체 및 이를 포함하는 세포
CN116948012B (zh) * 2022-04-13 2024-07-26 星奕昂(上海)生物科技有限公司 增强细胞功能的cd16抗剪切突变体
CN116716342A (zh) * 2022-06-22 2023-09-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
WO2024067682A1 (zh) * 2022-09-29 2024-04-04 上海先博生物科技有限公司 工程改造的免疫效应细胞及其组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734119A2 (en) * 1995-05-03 2006-12-20 Applied Research Systems ARS Holding N.V. CD16-II variants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US121788A (en) * 1871-12-12 Improvement in match-boxes
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2007515185A (ja) 2003-12-22 2007-06-14 カイロン コーポレイション 免疫応答障害に対する処置ストラテジーのための診断法としてのＦｃレセプター多型の使用
EP2112162B1 (en) * 2004-07-10 2015-01-14 Fox Chase Cancer Center Genetically modified human natural killer cell lines
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
MX2008000030A (es) * 2005-07-11 2008-04-02 Macrogenics Inc Metodos para el tratamiento de enfermedad autoinmune utilizando anticuerpos anti-cd16a humanizados.
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2010040091A1 (en) * 2008-10-03 2010-04-08 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Novel dna nanostructures that promote cell-cell interaction and use thereof
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
AU2015235852B2 (en) 2014-03-28 2019-08-15 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734119A2 (en) * 1995-05-03 2006-12-20 Applied Research Systems ARS Holding N.V. CD16-II variants

Also Published As

Publication number Publication date
CA2944199A1 (en) 2015-10-01
AU2022204134A1 (en) 2022-06-30
US20200017570A1 (en) 2020-01-16
AU2019250155B2 (en) 2022-03-17
AU2022204134B2 (en) 2024-11-28
WO2015148926A9 (en) 2016-11-10
JP2017511135A (ja) 2017-04-20
EP3122769B1 (en) 2023-02-22
AU2019250155A1 (en) 2019-10-31
US20240417441A1 (en) 2024-12-19
CN113699159A (zh) 2021-11-26
US20170174743A1 (en) 2017-06-22
CA2944199C (en) 2023-08-15
EP4227318A1 (en) 2023-08-16
ES2941679T3 (es) 2023-05-24
EP3122769A1 (en) 2017-02-01
US11370825B2 (en) 2022-06-28
JP2021035390A (ja) 2021-03-04
WO2015148926A1 (en) 2015-10-01
JP7091423B2 (ja) 2022-06-27
JP7575426B2 (ja) 2024-10-29
JP2022121484A (ja) 2022-08-19
AU2015235852A1 (en) 2016-10-20
US12098182B2 (en) 2024-09-24
US20210332103A1 (en) 2021-10-28
CN106715467A (zh) 2017-05-24
JP6795399B2 (ja) 2020-12-02
US10464989B2 (en) 2019-11-05
JP2025004257A (ja) 2025-01-14
PT3122769T (pt) 2023-04-24
CN106715467B (zh) 2021-07-27

Similar Documents

Publication Publication Date Title
AU2022204134B2 (en) Polypeptides, cells, and methods involving engineered cd16
Jing et al. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells
Lemieux et al. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10
US20240124550A1 (en) Recombinant immune cells, methods of making, and methods of use
Perišić Nanut et al. Cystatin F affects natural killer cell cytotoxicity
US12345711B2 (en) Methods to determine antibody activity in tumor samples
CN107523546A (zh) 一种高效稳定表达抗体的nk细胞及其用途
CN112601546A (zh) Plap-car-效应细胞
HK40101335A (en) Polypeptides, cells, and methods involving engineered cd16
HK40064550A (en) Polypeptides, cells, and methods involving engineered cd16
HK1237796B (zh) 涉及经工程改造的cd16的多肽、细胞和方法
HK1237796A1 (en) Polypeptides, cells, and methods involving engineered cd16
HK40025672A (en) Recombinant immune cells, methods of making, and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)